The data point

On 26 October 2026, Avacta (LSE:AVCT) reported that patients with salivary gland cancer treated with faridoxorubicin in its Phase 1a/1b study had a median progression-free survival of 11.4 months. The company compared that with historical benchmarks of six to 6.7 months, describing the outcome as a near doubling. The results were presented as a poster at the European Society for Medical Oncology congress in Madrid the same day.

About the company

Avacta is a UK biotechnology company developing cancer therapies built on its pre|CISION platform. The platform attaches a cancer drug to a peptide that is cleaved by fibroblast activation protein, an enzyme found in high concentrations in the tissue surrounding many solid tumours. The aim is to keep the active drug inactive in the bloodstream and release it mainly where it is needed, reducing exposure for healthy tissue.

Its lead programme, faridoxorubicin, applies the idea to doxorubicin, a long-established chemotherapy. A second candidate, AVA6103, is in the FOCUS-01 Phase 1 trial and uses the same approach with a different payload. The company is clinical-stage, so its value depends on trial results, partnering and access to funding rather than on product sales.

What was measured

Faridoxorubicin, also known as AVA6000, is a version of the established chemotherapy doxorubicin that is designed to be released mainly inside tumours. LSE:AVCT's pre|CISION technology attaches the drug to a peptide that is cleaved by fibroblast activation protein, an enzyme concentrated in the tissue surrounding many solid tumours, with the aim of reducing exposure in healthy tissue.

The analysis covered 32 patients treated at doses of 310 mg/m² or higher, drawn from 51 salivary gland cancer patients enrolled across doses and cohorts. Certain rare subtypes and more heavily pre-treated patients were excluded. The lower bound of the 95% confidence interval was seven months, the upper bound had not been reached, and median overall survival had also not been reached at the 5 October data cut-off. There were three partial responses and six minor responses.

Biopsy data showed about 100 times more released doxorubicin in tumour tissue than in plasma, and imaging suggested the target enzyme remained detectable during prolonged treatment, supporting continued drug release over many cycles.

Why it matters

Salivary gland cancers have few effective treatment Options once advanced, so a durable disease control signal is clinically relevant. For Avacta, the data also serve as evidence that its delivery platform works in patients, which supports the next-generation candidate AVA6103 and its partnering discussions. Chief executive Christina Coughlin said the datasets support the platform's ability to deliver potent chemotherapy payloads over long periods.

The poster's senior author, Dr Alan Ho of Memorial Sloan Kettering Cancer Center, described the findings as promising for a patient group with limited effective treatment options. Responses lasted 18.7 to 72 weeks, which indicates that some responses were sustained for well over a year.

Limits of the evidence

The figures come from a non-randomised, early-stage trial and a selected subset of patients, so they do not establish superiority over existing therapies. Historical benchmarks may involve different patient populations, and the exclusion of some subtypes and heavily pre-treated patients could flatter the comparison. Safety data were not detailed. Confirming benefit would ultimately require controlled studies, which are costly.

Funding is a further constraint. In October Avacta raised about £12.5m at 68p per share, which it said would extend its cash runway into the second quarter of 2027. That leaves limited time before further financing or a Partnership is likely to be needed, adding dilution risk for shareholders.

Understanding progression-free survival

Progression-free survival measures how long patients live without their cancer growing or spreading. A median of 11.4 months means half of the patients in the analysed group were free of progression for longer than that period. The company's comparison with historical benchmarks of six to 6.7 months is a standard way of putting an early result in context, but it is not a substitute for a controlled comparison, because historical groups can differ from the trial population in age, prior treatment and disease stage.

The confidence interval offers a further guide. A lower bound of seven months suggests that, even allowing for statistical uncertainty in a group of 32 patients, the result sits above the benchmark range. The fact that the upper bound and median overall survival had not been reached at the 5 October cut-off means follow-up was still incomplete, so the figures may change as data mature.

The tumour data

The biopsy finding of about 100 times more released doxorubicin in tumour tissue than in plasma speaks to the mechanism rather than to clinical benefit, but it is the kind of evidence that supports the design rationale. Imaging indicating that the target enzyme remained detectable during prolonged treatment adds to that, as it suggests the release mechanism may not fade over repeated cycles. Together with responses lasting 18.7 to 72 weeks, the data describe a platform that behaved as intended in this group of patients.

Funding and timeline pressures

Developing cancer medicines is capital-intensive, and the company's cash runway extends into the second quarter of 2027 after the October raise of about £12.5m at 68p per share. Against that timeline, the markers described by the company are close together: expansion cohort data in soft tissue sarcoma and triple-negative breast cancer, longer-term survival data from the salivary gland group, tumour pharmacokinetic findings for AVA6103 in late 2026 or early 2027 and initial efficacy data in the first half of 2027. A partnering agreement could provide non-dilutive funding, but there is no assurance that one will be signed, and each readout will shape how potential partners and investors view the platform.

What comes next

LSE:AVCT has said that expansion cohorts in soft tissue sarcoma and triple-negative breast cancer are maturing, and that longer-term survival data from the salivary gland group are awaited. For AVA6103, now in the FOCUS-01 Phase 1 trial, the company expects tumour pharmacokinetic findings in late 2026 or early 2027 and initial efficacy data in the first half of 2027. Those readouts, and any partnering agreement, are the disclosed markers by which progress will be judged. The 4 November announcement on a dual-payload candidate shows the platform being extended beyond single payloads.